Monoclonal Antibody Development Service
Bladder cancer is a prevalent malignancy and presents a demand for novel therapeutic approaches. Recent advancements in antibody and protein technologies have paved the way for innovative engineering strategies, resulting in the development of cutting-edge therapeutic entities with unique mechanisms of action. Alfa Cytology offers state-of-the-art research services and essential platforms to ensure you stay ahead of the curve in monoclonal antibody development for bladder cancer.
Mechanisms of Monoclonal Antibody Therapy
Monoclonal antibody therapy utilizes the precise binding capacity of monoclonal antibodies to modulate or regulate biological processes for disease treatment. These antibodies can exert their effects through a range of mechanisms.
Fig.1 Overview of antibody-based drugs for the treatment of bladder cancer. (Bogen, J. P., et al. 2021)
Monoclonal Antibody Therapy for Bladder Cancer
Bladder cancer is a prevalent malignancy, and for patients with advanced or refractory disease, conventional treatments may have limited efficacy. In recent years, monoclonal antibody therapy has emerged as a novel biological therapeutic strategy that has garnered significant attention and research interest. These interventions harness the specific binding capacity of monoclonal antibodies to target bladder cancer biomarkers or signaling pathways, thereby impeding tumor growth, metastasis, and recurrence. A variety of monoclonal antibodies are developed for bladder cancer therapy.
| Drug (Target) |
Combined with (or compared to) |
Disease |
Phase |
Status |
| Lirilumab (KIR2DL) |
Nivolumab |
Bladder Cancer |
I |
Active, not recruiting |
| Vofatamab (FGFR3) |
Docetaxel |
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases |
I/II |
Terminated (program has been put on hold by the sponsor)
Termination (Program terminated due to sponsorship) |
| Pembrolizumab |
Bladder Cancer |
I |
Terminated (Terminated due to safety concerns) |
| Pembrolizumab |
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases |
I/II |
Terminated (program has been put on hold by the sponsor)
Terminated (program has been put on hold by the sponsor) |
Our Services
Alfa Cytology's monoclonal antibody development service provides a comprehensive solution for researchers and pharmaceutical companies, encompassing the entire process from project consultation to antibody expression and purification. We aim to facilitate the development of innovative therapeutic drugs specifically targeting bladder cancer.
Antigen Preparation
We provide specialized services for the extraction and preparation of antigens from bladder cancer-related sources. This includes sourcing, purifying, and validating antigens from cell lines or animal models, ensuring their quality and purity meet requirements.
Animal Immunization
Our team possesses extensive experience in conducting effective immunization processes in mice, rats, or other animal models. We rigorously control the immunization protocols to ensure the generation of robust immune responses, maximizing the specificity and affinity of monoclonal antibodies.
Antibody Development
Through a combination of cutting-edge fusion cell technology and high-throughput screening methods, we expedite the identification and characterization of monoclonal antibodies with high specificity and affinity. This phase involves meticulous screening, selection, and validation processes.
Antibody Expression and Purification
Following successful antibody identification, we proceed to express and purify the antibodies using advanced techniques such as cell culture, protein expression, and chromatography. This ensures the production of high-quality monoclonal antibodies with optimal purity and activity.
Contact Us
Alfa Cytology is committed to providing customers with high-quality, specialized services to promote scientific research in the field of bladder cancer. If you are interested in our services, please contact us for more detailed information.
Reference
- Bogen, J. P., Grzeschik, J., and et al. Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. Frontiers in oncology, 2021, 11, 672262.
For research use only. Not intended for any clinical use.
Related Services
